Abiomed (ABMD) Tops Q1 EPS by 40c, Raises Lower End Of FY 2017 Guidance By $5M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ABIOMED (ABMD) PT Raised to $180 at Leerink Partners; Reiterates Outperform
July 28, 2017 10:05 AM EDTLeerink Partners raised its price target on ABIOMED (NASDAQ: ABMD) to $180.00 (from $165.00) while maintaining a Outperform rating. ABMD raised the low end of its FY2018 sales guidance by $5M, highlighting an even higher level of confidence in the sustainability of recent Impella adoption... More
